Darifenacin

Generic Name
Darifenacin
Brand Names
Emselex, Enablex
Drug Type
Small Molecule
Chemical Formula
C28H30N2O2
CAS Number
133099-04-4
Unique Ingredient Identifier
APG9819VLM
Background

Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.

Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention.
...

Indication

For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Associated Conditions
Overactive Bladder Syndrome (OABS)
Associated Therapies
-
Clinical Trials
Related News

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Darifenacin
Drug: Tolterodine
Drug: Placebo
First Posted Date
2006-12-20
Last Posted Date
2008-01-15
Lead Sponsor
Novartis
Target Recruit Count
162
Registration Number
NCT00413790
Locations
🇺🇸

Investigative Site, Dallas, Texas, United States

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Phase 4
Completed
Conditions
Overactive Bladder (OAB)
Interventions
Drug: Darifenacin
First Posted Date
2006-08-18
Last Posted Date
2008-01-15
Lead Sponsor
Novartis
Target Recruit Count
500
Registration Number
NCT00366002
Locations
🇺🇸

Investigative Site, Milwaukee, Wisconsin, United States

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Phase 3
Completed
Conditions
Overactive Bladder Syndrome
Interventions
Drug: Darifenacin
First Posted Date
2005-09-15
Last Posted Date
2008-01-17
Lead Sponsor
Novartis
Target Recruit Count
718
Registration Number
NCT00170755
Locations
🇺🇸

Novartis, East Hanover, New Jersey, United States

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

Phase 4
Completed
Conditions
Overactive Bladder
Interventions
Drug: Darifenacin
Drug: Placebo
First Posted Date
2005-09-15
Last Posted Date
2017-05-18
Lead Sponsor
Novartis
Target Recruit Count
400
Registration Number
NCT00171184
Locations
🇺🇸

Scott Department of Urology Baylor College of Medicine, Houston, Texas, United States

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Phase 3
Completed
Conditions
Overactive Bladder Syndrome
Interventions
Drug: Placebo
Drug: Darifenacin
First Posted Date
2005-09-15
Last Posted Date
2008-01-23
Lead Sponsor
Novartis
Target Recruit Count
445
Registration Number
NCT00171145
Locations
🇺🇸

Novartis, East Hanover, New Jersey, United States

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

First Posted Date
2005-09-15
Last Posted Date
2008-01-23
Lead Sponsor
Novartis
Target Recruit Count
150
Registration Number
NCT00170768
Locations
🇺🇸

Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

First Posted Date
2005-08-05
Last Posted Date
2008-01-24
Lead Sponsor
Novartis
Target Recruit Count
395
Registration Number
NCT00127270
Locations
🇺🇸

Research Protocol Management Specialists, Pittsburgh, Pennsylvania, United States

🇺🇸

Southern Oregon Health and Wellness, Medford, Oregon, United States

🇺🇸

Urologic Surgery Associates, Overland Park, Kansas, United States

and more 62 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy